E-LIB Suche - Ergebnisse für: Jan Kleijn, Huub

1

Exposure–Response Analyses for Belzutifan to Inform Dosing ..:

Marathe, Dhananjay D. ; Jauslin, Petra M. ; Jan Kleijn, Huub...
The Journal of Clinical Pharmacology. , 2024

Link: https://doi.org/10.1002/..

2

Pooled Modeling of Disease Progression in Two BACE1 Inhibit..:

Kleijn, Huub Jan ; Stone, Julie A ; Hu, Henry...
Alzheimer's & Dementia. 19 (2023) S24 - p. , 2023

Link: https://doi.org/10.1002/..

3

Population pharmacokinetic analyses for belzutifan to infor..:

Marathe, Dhananjay D. ; Jauslin, Petra M. ; Kleijn, Huub Jan...
CPT: Pharmacometrics & Systems Pharmacology. 12 (2023) 10 - p. 1499-1510 , 2023

Link: https://doi.org/10.1002/..

4

Predicted Bezlotoxumab Exposure in Patients Who Have Receiv..:

de Almeida, Camila ; Wong, Michael ; Kleijn, Huub Jan.
Clinical Therapeutics. 45 (2023) 4 - p. 356-362 , 2023

Link: https://doi.org/10.1016/..

5

Model‐Informed Selection of the Recommended Phase III Dose ..:

Vugmeyster, Yulia ; Ravula, Abhigyan ; Rouits, Elisabeth...
Clinical Pharmacology & Therapeutics. 115 (2023) 1 - p. 52-61 , 2023

Link: https://doi.org/10.1002/..

6

Population pharmacokinetic analysis of sparsentan in health..:

Wada, Russell ; Kleijn, Huub Jan ; Zhang, Lu.
CPT: Pharmacometrics & Systems Pharmacology. 12 (2023) 8 - p. 1080-1092 , 2023

Link: https://doi.org/10.1002/..

7

Eculizumab Pharmacokinetics and Pharmacodynamics in Patient..:

Singh, Pratap ; Gao, Xiang ; Kleijn, Huub Jan..
Frontiers in Neurology. 12 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

8

Population pharmacokinetic and exposure‐response analyses o..:

Jiang, Xuemin ; Wada, Russ ; Poland, Bill...
Clinical and Translational Science. 14 (2021) 3 - p. 942-953 , 2021

Link: https://doi.org/10.1111/..

9

Eculizumab Pharmacokinetics and Pharmacodynamics in Patient..:

Monteleone, Jonathan P. R. ; Gao, Xiang ; Kleijn, Huub Jan..
Frontiers in Neurology. 12 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

10

A time-to-event analysis of the exposure–response relations..:

Yee, Ka Lai ; Kleijn, Huub Jan ; Zajic, Stefan..
Journal of Pharmacokinetics and Pharmacodynamics. 47 (2020) 2 - p. 121-130 , 2020

Link: https://doi.org/10.1007/..

11

Design and rationale of two phase 3 randomised controlled t..:

Muccino, David R. ; Morice, Alyn H. ; Birring, Surinder S....
ERJ Open Research. 6 (2020) 4 - p. 00284-2020 , 2020

Link: https://doi.org/10.1183/..

12

Making Better Dose Decisions: Using Exposure‐Response Model..:

Li, Chi‐Chung ; Voss, Tiffini ; Kowalski, Ken...
Clinical and Translational Science. 13 (2020) 3 - p. 482-490 , 2020

Link: https://doi.org/10.1111/..

13

P3‐040: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE ..:

Stone, Julie A. ; Kleijn, Huub Jan ; Jaworowicz, David J....
Alzheimer's & Dementia. 15 (2019) 7S_Part_18 - p. , 2019

Link: https://doi.org/10.1016/..

14

P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INF..:

Rasmussen, Christian ; Kleijn, Huub Jan ; Kalinina, Juliya...
Alzheimer's & Dementia. 15 (2019) 7S_Part_11 - p. , 2019

Link: https://doi.org/10.1016/..

15

P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APEC..:

Stone, Julie A. ; Kleijn, Huub Jan ; Xu, Ming...
Alzheimer's & Dementia. 15 (2019) 7S_Part_4 - p. , 2019

Link: https://doi.org/10.1016/..